Grade III meningioma
MONDO:0020634A malignant meningioma with aggressive clinical course. It recurs in approximately 50-78% of the cases. This category includes the anaplastic (malignant) meningioma, papillary meningioma, and rhabdoid meningioma.
Also known as: WHO grade III meningioma, grade 3 meningioma, grade III meningioma, meningioma, malignant
1465 clinical trials for this condition and its sub-types, 14 tagged with Grade III meningioma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Grade III meningioma
-
Anaplastic meningioma 9 trials
-
Proton boost: new hope for tough brain tumors?
Disease control OngoingThis study tests a higher dose of a precise type of radiation called proton therapy for people with aggressive meningiomas (brain tumors). The goal is to find a safe dose that can better control the tumor after surgery. The study includes 21 participants with either grade II or g…
Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
Immunotherapy meets radiation in fight against recurrent meningioma
Disease control OngoingThis study is for people with a rare, aggressive brain tumor called high-grade meningioma that has come back after radiation. It tests whether adding immunotherapy drugs (nivolumab with or without ipilimumab) to precise, high-dose radiation can help shrink the tumor or slow its g…
Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Immunotherapy drug shows promise for tough brain tumor
Disease control OngoingThis study tested the immunotherapy drug pembrolizumab in 26 people with high grade meningioma that came back or remained after treatment. The goal was to see if the drug could stop the tumor from growing for at least 6 months. Participants received pembrolizumab and had regular …
Phase 2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New combo therapy aims to stop returning brain tumors
Disease control OngoingThis phase II trial tests whether combining stereotactic radiosurgery (precise, high-dose radiation) with the immunotherapy drug pembrolizumab (Keytruda) can help control recurrent meningioma, a type of brain tumor. The study enrolls 35 adults whose tumors have returned after pri…
Phase 2 • Sponsor: Nancy Ann Oberheim Bush, MD • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New radiation strategy aims to tackle tough brain tumors
Disease control PausedThis early-phase trial tests whether giving higher doses of radiation, guided by special PET/MRI scans, is safe for people with high-risk meningiomas (aggressive or recurrent brain tumors). About 24 adults will receive one of four radiation dose levels to find the highest dose th…
Phase 1 • Sponsor: Thomas Jefferson University • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC